You are here

Study Finds No CV Benefit from Multivitamins—Again

A meta-analysis that included 18 million participants found no protection from heart disease or stroke.

The U.S. Preventive Services Task Force and the National Institutes of Health recommend against taking multivitamins to prevent chronic diseases. Yet millions of Americans continue to pop the pills. According to data from the National Health and Nutrition Examination Survey, about 30% of the American population are multivitamin users.

A meta-analysis published today in Circulation: Cardiovascular Quality and Outcomes added another brick in the wall of evidence that multivitamins have no cardiovascular benefits.

The meta-analysis included 18 prospective cohort studies and randomized trials, encompassing more two million participants and 18 million person-years of follow-up.

When the research team of investigators from Johns Hopkins and other universities combined all the data, they found no statistical associations between multivitamin supplements and CVD mortality, CHD mortality, stroke mortality, or stroke incidence.

They noted that multivitamin use is associated with lower risk of CHD incidence in studies done outside the United States while no benefit has been found by the studies performed in this country. They chalk up the discrepancy to unmeasured confounding rather than true regional differences.

Source: Circulation: Cardiovascular Quality and Outcomes

More Headlines

Agency says products for sexual enhancement, weight loss, and bodybuilding have hidden drugs and chemicals.
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.
Some of that can be chalked up to the differences in cost of living from place to place, but not all.
Health plans expected to continue pushing for value-based payment arrangements.
One of the proposed changes makes remote patient monitoring an allowable cost.
European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab.
Puts down $700 million to buy nearly 50% of Samsung.
The move comes even though some of the pharma company’s rivals have promised to raise prices only once a year.